上海生生转道港股IPO 股权转让成高管“点金术”

Core Viewpoint - Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, facing scrutiny over internal control issues despite its industry advantages and market position [1] Group 1: Company Overview - Shanghai Shengsheng is a leading integrated temperature-controlled supply chain service provider in the pharmaceutical and life sciences sector, focusing on clinical trial temperature-controlled supply chain services [2] - The company achieved revenues of 614 million yuan, 654 million yuan, and 538 million yuan for the years 2023, 2024, and the first three quarters of 2025, respectively, with profits of 92.03 million yuan, 26.396 million yuan, and 113 million yuan during the same periods [2] - The revenue structure is primarily derived from clinical trial temperature-controlled supply chain services, which consistently account for over 80% of total revenue [2] Group 2: Market Dynamics - The growth in Shanghai Shengsheng's performance is driven by the expanding market size and technological demands, with the clinical trial temperature-controlled service market in China growing from 2 billion yuan in 2020 to 3.6 billion yuan in 2024 [3] - The company holds both GMP and GDP certifications, establishing a nationwide service network to meet the stringent temperature control and safety requirements of the pharmaceutical industry [3] Group 3: Financial Performance and Challenges - The accounts receivable of Shanghai Shengsheng increased significantly, with trade receivables of 157 million yuan, 192 million yuan, and 220 million yuan during the reporting period, and the turnover days for trade receivables were 98 days, 98 days, and 105 days, respectively [4] - The company acknowledged that some transactions with clients are settled on credit, which could adversely affect its cash flow and business operations if clients fail to pay on time [4] Group 4: Governance Issues - Concerns regarding internal control governance arose when the actual controllers borrowed funds to increase their shareholding and subsequently transferred shares at a premium, raising regulatory scrutiny [5] - The significant difference in share transfer prices has led to questions from regulators, although the company has stated that there are reasonable backgrounds for these price variations [5] - In 2024, the company reported a substantial drop in profits primarily due to share-based payment expenses amounting to 72.12 million yuan, with a significant portion of these expenses attributed to a few high-salaried employees [6]